Ocugen Inc (NASDAQ: OCGN) shares are trading lower by 22.8% at $2.54 after the company announced the FDA declined to issue an EUA for COVAXIN for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 2 to 18 years of age.
Ocugen (NASDAQ:OCGN) reported its Q4 earnings results on Friday, February 25, 2022 at 07:30 AM.
Here's what investors need to know about the announcement.
Companies Reporting Before The Bell
• ACM Research (NASDAQ:ACMR) is estimated to report quarterly earnings at $0.64 per share on revenue of $89.53 million.
Gainers
Tenneco Inc. (NYSE: TEN) shares surged 93.9% to close at $19.35 on Wednesday after the company announced it will be acquired by Apollo Funds. Tenneco also reported a Q4 loss of $0.11 per share.
Ocugen Inc (NASDAQ: OCGN) shares are trading lower by 19.6% at $3.40 Wednesday morning after the company announced pricing of a $53.5 million public offering of common stock.
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study
U.S. stocks pared back some losses toward the end of trading on Tuesday. Russian President Vladimir Putin said he would recognize the independence of two Russian-led breakaway regions of Ukraine and ordered Russian troops to go into eastern Ukraine.